vs
Equinix（EQIX）与硕腾（ZTS）财务数据对比。点击上方公司名可切换其他公司
Equinix的季度营收约是硕腾的1.0倍（$2.4B vs $2.4B），硕腾净利率更高（25.3% vs 11.0%，领先14.3%），Equinix同比增速更快（8.8% vs 3.0%），过去两年Equinix的营收复合增速更高（5.9% vs 4.4%）
Equinix是总部位于美国加利福尼亚州雷德伍德城的跨国企业，主营互联网连接服务与数据中心托管业务，旗下数据中心此前常被业内称为“运营商酒店”，2015年1月公司正式转型为房地产投资信托基金（REIT）。
硕腾是全球规模最大的动物保健制药企业，专注于宠物与家畜用药品、疫苗的研发和生产，前身为制药巨头辉瑞旗下的动物保健业务板块，辉瑞剥离多数股权后成为完全独立的企业。目前公司产品直销约45个国家，在全球超过100个国家和地区销售，海外业务占总营收的50%左右。
EQIX vs ZTS — 直观对比
营收规模更大
EQIX
是对方的1.0倍
$2.4B
营收增速更快
EQIX
高出5.7%
3.0%
净利率更高
ZTS
高出14.3%
11.0%
两年增速更快
EQIX
近两年复合增速
4.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.4B | $2.4B |
| 净利润 | $265.0M | $603.0M |
| 毛利率 | 50.5% | 70.2% |
| 营业利润率 | 17.4% | 31.9% |
| 净利率 | 11.0% | 25.3% |
| 营收同比 | 8.8% | 3.0% |
| 净利润同比 | -22.7% | 3.8% |
| 每股收益（稀释后） | $2.70 | $1.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EQIXZTS
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.4B | $2.4B | ||
| Q3 25 | $2.3B | $2.4B | ||
| Q2 25 | $2.3B | $2.5B | ||
| Q1 25 | $2.2B | $2.2B | ||
| Q4 24 | $2.3B | $2.3B | ||
| Q3 24 | $2.2B | $2.4B | ||
| Q2 24 | $2.2B | $2.4B |
净利润EQIXZTS
| Q1 26 | $265.0M | — | ||
| Q4 25 | $265.0M | $603.0M | ||
| Q3 25 | $374.0M | $721.0M | ||
| Q2 25 | $368.0M | $718.0M | ||
| Q1 25 | $343.0M | $631.0M | ||
| Q4 24 | $-14.0M | $581.0M | ||
| Q3 24 | $297.0M | $682.0M | ||
| Q2 24 | $301.0M | $624.0M |
毛利率EQIXZTS
| Q1 26 | 50.5% | — | ||
| Q4 25 | 50.5% | 70.2% | ||
| Q3 25 | 50.7% | 71.5% | ||
| Q2 25 | 52.0% | 73.6% | ||
| Q1 25 | 51.3% | 72.0% | ||
| Q4 24 | 47.1% | 69.5% | ||
| Q3 24 | 50.1% | 70.6% | ||
| Q2 24 | 49.9% | 71.7% |
营业利润率EQIXZTS
| Q1 26 | 17.4% | — | ||
| Q4 25 | 17.4% | 31.9% | ||
| Q3 25 | 20.5% | 37.0% | ||
| Q2 25 | 21.9% | 36.7% | ||
| Q1 25 | 20.6% | 36.5% | ||
| Q4 24 | 4.6% | 31.6% | ||
| Q3 24 | 19.3% | 36.6% | ||
| Q2 24 | 20.2% | 33.0% |
净利率EQIXZTS
| Q1 26 | 11.0% | — | ||
| Q4 25 | 11.0% | 25.3% | ||
| Q3 25 | 16.1% | 30.0% | ||
| Q2 25 | 16.3% | 29.2% | ||
| Q1 25 | 15.4% | 28.4% | ||
| Q4 24 | -0.6% | 25.1% | ||
| Q3 24 | 13.5% | 28.6% | ||
| Q2 24 | 13.9% | 26.4% |
每股收益（稀释后）EQIXZTS
| Q1 26 | $2.70 | — | ||
| Q4 25 | $2.70 | $1.37 | ||
| Q3 25 | $3.81 | $1.63 | ||
| Q2 25 | $3.75 | $1.61 | ||
| Q1 25 | $3.50 | $1.41 | ||
| Q4 24 | $-0.19 | $1.29 | ||
| Q3 24 | $3.10 | $1.50 | ||
| Q2 24 | $3.16 | $1.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.2B | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $14.2B | $3.3B |
| 总资产 | $40.1B | $15.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EQIXZTS
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | — | ||
| Q3 25 | $2.9B | $2.1B | ||
| Q2 25 | $4.5B | $1.4B | ||
| Q1 25 | $3.7B | $1.7B | ||
| Q4 24 | $3.6B | $2.0B | ||
| Q3 24 | $3.2B | $1.7B | ||
| Q2 24 | $2.0B | $1.6B |
总债务EQIXZTS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $17.3B | — | ||
| Q2 25 | $18.1B | — | ||
| Q1 25 | $15.9B | — | ||
| Q4 24 | $15.3B | — | ||
| Q3 24 | $15.4B | — | ||
| Q2 24 | $14.5B | — |
股东权益EQIXZTS
| Q1 26 | $14.2B | — | ||
| Q4 25 | $14.2B | $3.3B | ||
| Q3 25 | $14.2B | $5.4B | ||
| Q2 25 | $14.1B | $5.0B | ||
| Q1 25 | $13.9B | $4.7B | ||
| Q4 24 | $13.5B | $4.8B | ||
| Q3 24 | $13.6B | $5.2B | ||
| Q2 24 | $12.3B | $5.0B |
总资产EQIXZTS
| Q1 26 | $40.1B | — | ||
| Q4 25 | $40.1B | $15.5B | ||
| Q3 25 | $38.1B | $15.2B | ||
| Q2 25 | $38.8B | $14.5B | ||
| Q1 25 | $36.1B | $14.1B | ||
| Q4 24 | $35.1B | $14.2B | ||
| Q3 24 | $35.4B | $14.4B | ||
| Q2 24 | $32.9B | $14.2B |
负债/权益比EQIXZTS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.22× | — | ||
| Q2 25 | 1.28× | — | ||
| Q1 25 | 1.14× | — | ||
| Q4 24 | 1.13× | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 1.18× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $893.0M |
| 自由现金流经营现金流 - 资本支出 | — | $732.0M |
| 自由现金流率自由现金流/营收 | — | 30.7% |
| 资本支出强度资本支出/营收 | — | 6.7% |
| 现金转化率经营现金流/净利润 | — | 1.48× |
| 过去12个月自由现金流最近4个季度 | — | $2.3B |
8季度趋势，按日历期对齐
经营现金流EQIXZTS
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $893.0M | ||
| Q3 25 | $1.0B | $938.0M | ||
| Q2 25 | $944.0M | $486.0M | ||
| Q1 25 | $809.0M | $587.0M | ||
| Q4 24 | $981.0M | $905.0M | ||
| Q3 24 | $758.0M | $951.0M | ||
| Q2 24 | $912.0M | $502.0M |
自由现金流EQIXZTS
| Q1 26 | — | — | ||
| Q4 25 | $-292.0M | $732.0M | ||
| Q3 25 | $-122.0M | $805.0M | ||
| Q2 25 | $-45.0M | $308.0M | ||
| Q1 25 | $59.0M | $438.0M | ||
| Q4 24 | $-6.0M | $689.0M | ||
| Q3 24 | $34.0M | $784.0M | ||
| Q2 24 | $264.0M | $370.0M |
自由现金流率EQIXZTS
| Q1 26 | — | — | ||
| Q4 25 | -12.1% | 30.7% | ||
| Q3 25 | -5.3% | 33.5% | ||
| Q2 25 | -2.0% | 12.5% | ||
| Q1 25 | 2.7% | 19.7% | ||
| Q4 24 | -0.3% | 29.7% | ||
| Q3 24 | 1.5% | 32.8% | ||
| Q2 24 | 12.2% | 15.7% |
资本支出强度EQIXZTS
| Q1 26 | — | — | ||
| Q4 25 | 59.3% | 6.7% | ||
| Q3 25 | 49.1% | 5.5% | ||
| Q2 25 | 43.8% | 7.2% | ||
| Q1 25 | 33.7% | 6.7% | ||
| Q4 24 | 43.7% | 9.3% | ||
| Q3 24 | 32.9% | 7.0% | ||
| Q2 24 | 30.0% | 5.6% |
现金转化率EQIXZTS
| Q1 26 | — | — | ||
| Q4 25 | 4.32× | 1.48× | ||
| Q3 25 | 2.71× | 1.30× | ||
| Q2 25 | 2.57× | 0.68× | ||
| Q1 25 | 2.36× | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 2.55× | 1.39× | ||
| Q2 24 | 3.03× | 0.80× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EQIX
暂无分部数据
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
